643
Participants
Start Date
January 19, 2018
Primary Completion Date
October 3, 2020
Study Completion Date
October 3, 2020
Dolutegravir
One 50 mg DTG tablet was administered orally once daily
Emtricitabine/tenofovir alafenamide
One fixed-dose combination tablet (FTC 200 mg/TAF 25 mg) was administered orally once daily
Emtricitabine/tenofovir disoproxil fumarate
One fixed-dose combination tablet (FTC 200 mg/TDF 300 mg) was administered orally once daily
Efavirenz/emtricitabine/tenofovir disoproxil fumarate
One fixed-dose combination tablet (EFV 600 mg/FTC 200 mg/TDF 300 mg) was administered orally once daily
Soweto IMPAACT CRS, Johannesburg
Wits RHI Shandukani Research Centre CRS, Johannesburg
Umlazi CRS, Durban
Famcru Crs, Tygerberg
Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok
Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio de Janeiro
Univ. of Florida Jacksonville NICHD CRS, Jacksonville
Pediatric Perinatal HIV Clinical Trials Unit CRS, Miami
Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Mai
Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai
Byramjee Jeejeebhoy Medical College (BJMC) CRS, Pune
Gaborone CRS, Gaborone
Molepolole CRS, Gaborone
Kilimanjaro Christian Medical Centre (KCMC), Moshi
Baylor-Uganda CRS, Kampala
Seke North CRS, Chitungwiza
St Mary's CRS, Chitungwiza
Harare Family Care CRS, Harare
SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte
Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro
Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS, Rio de Janeiro
National Institute of Allergy and Infectious Diseases (NIAID)
NIH